Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 283,19 pts
-0.82%


Last updated : 17/11/2026 - 11h51
🏠 Home   ➤    Stock news

Adocia shares drop nearly 10% and erase part of their weekly rebound

The Lyon-based biotech faces heavy profit-taking. The decline follows the presentation of new preclinical data in Washington, on a Paris market trending lower.


Adocia shares drop nearly 10% and erase part of their weekly rebound

A weekly surge partly erased, with the MM200 above the share price

Adocia falls 9.91% to €3.80, well off the day's low, but the decline remains moderate relative to the week: the stock still shows a 25.07% gain over seven days, after a rebound that had carried it past several resistance levels. This session places the stock among the largest decliners across the entire Paris listing, while the CAC 40 loses 1%.

The share price remains above its MM20 (a gap of +18.44%) but falls below its MM200 at €4.34, a gap of -12.40%: the €4.67 level crossed on Monday is now a thing of the past, and the stock has dropped back below the €4.34 threshold.

Data on AdoXL Sema and cash runway funded until Q1 2028

On 16 November, at the ObesityWeek congress in Washington, the company presented preclinical data on AdoXL Sema, an application of its AdoXLong platform to semaglutide. Obtained in rats and pigs, these results support, according to Adocia, monthly administration in humans, with weight loss comparable to, and not superior to, that of the reference molecule.

On the financing side, the €8.4 million cash position as of 30 September, supplemented by a €7 million financing and by the cost reduction undertaken since September, extends the company's financing horizon to the first quarter of 2028.

Among the risks cited when the nine-month 2026 results were published (29 October 2026) is the dependence on a milestone payment of $20 million, conditional on obtaining marketing authorisation for BioChaperone Lispro in China.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Revenue growth: -97 %
Guidance from the release
  • « Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
  • Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
  • Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
  • Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
  • Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
  • Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
  • Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours